In summary, palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy significantly improved the PFS overall response rate, and overall survival compared to placebo plus endocrine therapy in patients with metastatic HR-positive HER2-negative BC, both in first- and second-line disease setting. This evidence concerns the gene ERBB2 and breast cancer.